NICE Approves Ruxolitinib Cream for Treating Vi...

By HEOR Staff Writer

February 25, 2026

NICE Backs Ruxolitinib Cream Vitiligo Treatment Ruxolitinib cream vitiligo therapy has received a major endorsement from the National Institute for Health and Care Excellence (NICE), w...
Merck Portfolio Optimization: Strategic Reorganization for Enhanced Commercia...
Economic Burden NSCLC: A Systematic Review of Healthcare Costs and Resource U...
Administrative Court Error Complicates Infarmed Vaccine Data Transparency
EMA Validation of ENHERTU Breast Cancer Treatment for Post-Neoadjuvant Therapy
NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection w...
Zorginstituut Nederland’s Lecanemab Health Insurance Rejection: Implica...
European Commission Approves Enhanced Wegovy Obesity Treatment Dose
Revised MenACWY Vaccination Strategy for Adolescents in Germany
Genotype ECG Prediction
Glofitamab Cost-Effectiveness: Conditional Reimbursement Insights for DLBCL T...
NICE Endorses Pegzilarginase for Treating Arginase Deficiency
Advancing Cancer Screening in Slovenia: A Pathway to Equitable Care